Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
|Articles|August 15, 2014
- BioPharm International-08-15-2014
- Volume 2014 eBook
- Issue 2
Standardizing Data Management
Author(s)Dana E. Vanderwall, James M. Vergis
Industry players form Allotrope Foundation to solve analytical data management problems.
Advertisement
Industry players form Allotrope Foundation to solve analytical data management problems.
Articles in this issue
about 12 years ago
Keys to Successful Method Transferabout 12 years ago
The Challenge of Finding the Unknownabout 12 years ago
Testing the Quality, Safety, and Efficacy of Insulin Biosimilarsabout 12 years ago
Using the Purity Quotient Difference to Assess Protein PurificationAdvertisement
Related to this article
Advertisement
Advertisement
Trending on BioPharm International
1
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
2
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
3
FAQ: When Big Pharma Drops a Drug Candidate, Who Picks It Up?
4
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
5